 | • レポートコード：MRC2-11QY03951 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経内分泌がんのグローバル市場について調査・分析したレポートです。種類別（化学療法、ソマトスタチン類似体、標的療法）市場規模、用途別（病院、診療所、腫瘍学センター、外来手術センター）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経内分泌がんの競争状況、市場シェア ・世界の神経内分泌がん市場：種類別市場規模 2015年-2020年（化学療法、ソマトスタチン類似体、標的療法） ・世界の神経内分泌がん市場：種類別市場規模予測 2021年-2026年（化学療法、ソマトスタチン類似体、標的療法） ・世界の神経内分泌がん市場：用途別市場規模 2015年-2020年（病院、診療所、腫瘍学センター、外来手術センター） ・世界の神経内分泌がん市場：用途別市場規模予測 2021年-2026年（病院、診療所、腫瘍学センター、外来手術センター） ・北米の神経内分泌がん市場分析：米国、カナダ ・ヨーロッパの神経内分泌がん市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経内分泌がん市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経内分泌がん市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経内分泌がん市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Novartis、Chiasma、Ipsen、Abbvie、Valeant、Jubilant、Teva、F.Hoffmann-La Roche、Advanced Accelerator、Mateon、Lexicon ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.
The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.
Market Analysis and Insights: Global Neuroendocrine Carcinoma Market
The global Neuroendocrine Carcinoma market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neuroendocrine Carcinoma Scope and Market Size
Neuroendocrine Carcinoma market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuroendocrine Carcinoma market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon
Market segment by Type, the product can be split into
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Market segment by Application, split into
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuroendocrine Carcinoma Revenue
1.4 Market by Type
1.4.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Chemotherapy
1.4.3 Somatostatin Analogs
1.4.4 Targeted Therapy
1.5 Market by Application
1.5.1 Global Neuroendocrine Carcinoma Market Share by Application: 2020 VS 2026
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Oncology Centres
1.5.5 Ambulatory Surgery Centres
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Neuroendocrine Carcinoma Market Perspective (2015-2026)
2.2 Global Neuroendocrine Carcinoma Growth Trends by Regions
2.2.1 Neuroendocrine Carcinoma Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuroendocrine Carcinoma Historic Market Share by Regions (2015-2020)
2.2.3 Neuroendocrine Carcinoma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuroendocrine Carcinoma Market Growth Strategy
2.3.6 Primary Interviews with Key Neuroendocrine Carcinoma Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Neuroendocrine Carcinoma Players by Market Size
3.1.1 Global Top Neuroendocrine Carcinoma Players by Revenue (2015-2020)
3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuroendocrine Carcinoma Market Concentration Ratio
3.2.1 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuroendocrine Carcinoma Revenue in 2019
3.3 Neuroendocrine Carcinoma Key Players Head office and Area Served
3.4 Key Players Neuroendocrine Carcinoma Product Solution and Service
3.5 Date of Enter into Neuroendocrine Carcinoma Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuroendocrine Carcinoma Historic Market Size by Type (2015-2020)
4.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Neuroendocrine Carcinoma Market Size by Application (2015-2020)
5.2 Global Neuroendocrine Carcinoma Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Neuroendocrine Carcinoma Market Size (2015-2020)
6.2 Neuroendocrine Carcinoma Key Players in North America (2019-2020)
6.3 North America Neuroendocrine Carcinoma Market Size by Type (2015-2020)
6.4 North America Neuroendocrine Carcinoma Market Size by Application (2015-2020)
7 Europe
7.1 Europe Neuroendocrine Carcinoma Market Size (2015-2020)
7.2 Neuroendocrine Carcinoma Key Players in Europe (2019-2020)
7.3 Europe Neuroendocrine Carcinoma Market Size by Type (2015-2020)
7.4 Europe Neuroendocrine Carcinoma Market Size by Application (2015-2020)
8 China
8.1 China Neuroendocrine Carcinoma Market Size (2015-2020)
8.2 Neuroendocrine Carcinoma Key Players in China (2019-2020)
8.3 China Neuroendocrine Carcinoma Market Size by Type (2015-2020)
8.4 China Neuroendocrine Carcinoma Market Size by Application (2015-2020)
9 Japan
9.1 Japan Neuroendocrine Carcinoma Market Size (2015-2020)
9.2 Neuroendocrine Carcinoma Key Players in Japan (2019-2020)
9.3 Japan Neuroendocrine Carcinoma Market Size by Type (2015-2020)
9.4 Japan Neuroendocrine Carcinoma Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Neuroendocrine Carcinoma Market Size (2015-2020)
10.2 Neuroendocrine Carcinoma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuroendocrine Carcinoma Market Size by Type (2015-2020)
10.4 Southeast Asia Neuroendocrine Carcinoma Market Size by Application (2015-2020)
11 India
11.1 India Neuroendocrine Carcinoma Market Size (2015-2020)
11.2 Neuroendocrine Carcinoma Key Players in India (2019-2020)
11.3 India Neuroendocrine Carcinoma Market Size by Type (2015-2020)
11.4 India Neuroendocrine Carcinoma Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Neuroendocrine Carcinoma Market Size (2015-2020)
12.2 Neuroendocrine Carcinoma Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuroendocrine Carcinoma Market Size by Type (2015-2020)
12.4 Central & South America Neuroendocrine Carcinoma Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Neuroendocrine Carcinoma Introduction
13.1.4 Pfizer Revenue in Neuroendocrine Carcinoma Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Neuroendocrine Carcinoma Introduction
13.2.4 Novartis Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Chiasma
13.3.1 Chiasma Company Details
13.3.2 Chiasma Business Overview
13.3.3 Chiasma Neuroendocrine Carcinoma Introduction
13.3.4 Chiasma Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.3.5 Chiasma Recent Development
13.4 Ipsen
13.4.1 Ipsen Company Details
13.4.2 Ipsen Business Overview
13.4.3 Ipsen Neuroendocrine Carcinoma Introduction
13.4.4 Ipsen Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.4.5 Ipsen Recent Development
13.5 Abbvie
13.5.1 Abbvie Company Details
13.5.2 Abbvie Business Overview
13.5.3 Abbvie Neuroendocrine Carcinoma Introduction
13.5.4 Abbvie Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.5.5 Abbvie Recent Development
13.6 Valeant
13.6.1 Valeant Company Details
13.6.2 Valeant Business Overview
13.6.3 Valeant Neuroendocrine Carcinoma Introduction
13.6.4 Valeant Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.6.5 Valeant Recent Development
13.7 Jubilant
13.7.1 Jubilant Company Details
13.7.2 Jubilant Business Overview
13.7.3 Jubilant Neuroendocrine Carcinoma Introduction
13.7.4 Jubilant Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.7.5 Jubilant Recent Development
13.8 Teva
13.8.1 Teva Company Details
13.8.2 Teva Business Overview
13.8.3 Teva Neuroendocrine Carcinoma Introduction
13.8.4 Teva Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.8.5 Teva Recent Development
13.9 F.Hoffmann-La Roche
13.9.1 F.Hoffmann-La Roche Company Details
13.9.2 F.Hoffmann-La Roche Business Overview
13.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Introduction
13.9.4 F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.9.5 F.Hoffmann-La Roche Recent Development
13.10 Advanced Accelerator
13.10.1 Advanced Accelerator Company Details
13.10.2 Advanced Accelerator Business Overview
13.10.3 Advanced Accelerator Neuroendocrine Carcinoma Introduction
13.10.4 Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2015-2020)
13.10.5 Advanced Accelerator Recent Development
13.11 Mateon
10.11.1 Mateon Company Details
10.11.2 Mateon Business Overview
10.11.3 Mateon Neuroendocrine Carcinoma Introduction
10.11.4 Mateon Revenue in Neuroendocrine Carcinoma Business (2015-2020)
10.11.5 Mateon Recent Development
13.12 Lexicon
10.12.1 Lexicon Company Details
10.12.2 Lexicon Business Overview
10.12.3 Lexicon Neuroendocrine Carcinoma Introduction
10.12.4 Lexicon Revenue in Neuroendocrine Carcinoma Business (2015-2020)
10.12.5 Lexicon Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Neuroendocrine Carcinoma Key Market Segments
Table 2. Key Players Covered: Ranking by Neuroendocrine Carcinoma Revenue
Table 3. Ranking of Global Top Neuroendocrine Carcinoma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neuroendocrine Carcinoma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Chemotherapy
Table 6. Key Players of Somatostatin Analogs
Table 7. Key Players of Targeted Therapy
Table 8. Global Neuroendocrine Carcinoma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Neuroendocrine Carcinoma Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Neuroendocrine Carcinoma Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Neuroendocrine Carcinoma Market Share by Regions (2015-2020)
Table 12. Global Neuroendocrine Carcinoma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Neuroendocrine Carcinoma Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Neuroendocrine Carcinoma Market Growth Strategy
Table 18. Main Points Interviewed from Key Neuroendocrine Carcinoma Players
Table 19. Global Neuroendocrine Carcinoma Revenue by Players (2015-2020) (Million US$)
Table 20. Global Neuroendocrine Carcinoma Market Share by Players (2015-2020)
Table 21. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma as of 2019)
Table 22. Global Neuroendocrine Carcinoma by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Neuroendocrine Carcinoma Product Solution and Service
Table 25. Date of Enter into Neuroendocrine Carcinoma Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 28. Global Neuroendocrine Carcinoma Market Size Share by Type (2015-2020)
Table 29. Global Neuroendocrine Carcinoma Revenue Market Share by Type (2021-2026)
Table 30. Global Neuroendocrine Carcinoma Market Size Share by Application (2015-2020)
Table 31. Global Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 32. Global Neuroendocrine Carcinoma Market Size Share by Application (2021-2026)
Table 33. North America Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 35. North America Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 36. North America Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 37. North America Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 38. North America Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 39. Europe Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 41. Europe Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 43. Europe Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 45. China Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 46. China Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 47. China Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 48. China Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 49. China Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 50. China Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 51. Japan Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 53. Japan Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 55. Japan Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 59. Southeast Asia Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 61. Southeast Asia Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 63. India Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 64. India Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 65. India Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 66. India Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 67. India Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 68. India Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Neuroendocrine Carcinoma Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Neuroendocrine Carcinoma Market Share (2019-2020)
Table 71. Central & South America Neuroendocrine Carcinoma Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Neuroendocrine Carcinoma Market Share by Type (2015-2020)
Table 73. Central & South America Neuroendocrine Carcinoma Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Neuroendocrine Carcinoma Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Novartis Company Details
Table 81. Novartis Business Overview
Table 82. Novartis Product
Table 83. Novartis Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 84. Novartis Recent Development
Table 85. Chiasma Company Details
Table 86. Chiasma Business Overview
Table 87. Chiasma Product
Table 88. Chiasma Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 89. Chiasma Recent Development
Table 90. Ipsen Company Details
Table 91. Ipsen Business Overview
Table 92. Ipsen Product
Table 93. Ipsen Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 94. Ipsen Recent Development
Table 95. Abbvie Company Details
Table 96. Abbvie Business Overview
Table 97. Abbvie Product
Table 98. Abbvie Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 99. Abbvie Recent Development
Table 100. Valeant Company Details
Table 101. Valeant Business Overview
Table 102. Valeant Product
Table 103. Valeant Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 104. Valeant Recent Development
Table 105. Jubilant Company Details
Table 106. Jubilant Business Overview
Table 107. Jubilant Product
Table 108. Jubilant Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 109. Jubilant Recent Development
Table 110. Teva Business Overview
Table 111. Teva Product
Table 112. Teva Company Details
Table 113. Teva Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 114. Teva Recent Development
Table 115. F.Hoffmann-La Roche Company Details
Table 116. F.Hoffmann-La Roche Business Overview
Table 117. F.Hoffmann-La Roche Product
Table 118. F.Hoffmann-La Roche Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 119. F.Hoffmann-La Roche Recent Development
Table 120. Advanced Accelerator Company Details
Table 121. Advanced Accelerator Business Overview
Table 122. Advanced Accelerator Product
Table 123. Advanced Accelerator Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 124. Advanced Accelerator Recent Development
Table 125. Mateon Company Details
Table 126. Mateon Business Overview
Table 127. Mateon Product
Table 128. Mateon Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 129. Mateon Recent Development
Table 130. Lexicon Company Details
Table 131. Lexicon Business Overview
Table 132. Lexicon Product
Table 133. Lexicon Revenue in Neuroendocrine Carcinoma Business (2015-2020) (Million US$)
Table 134. Lexicon Recent Development
Table 135. Research Programs/Design for This Report
Table 136. Key Data Information from Secondary Sources
Table 137. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuroendocrine Carcinoma Market Share by Type: 2020 VS 2026
Figure 2. Chemotherapy Features
Figure 3. Somatostatin Analogs Features
Figure 4. Targeted Therapy Features
Figure 5. Global Neuroendocrine Carcinoma Market Share by Application: 2020 VS 2026
Figure 6. Hospital Case Studies
Figure 7. Clinics Case Studies
Figure 8. Oncology Centres Case Studies
Figure 9. Ambulatory Surgery Centres Case Studies
Figure 10. Neuroendocrine Carcinoma Report Years Considered
Figure 11. Global Neuroendocrine Carcinoma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Neuroendocrine Carcinoma Market Share by Regions: 2020 VS 2026
Figure 13. Global Neuroendocrine Carcinoma Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Neuroendocrine Carcinoma Market Share by Players in 2019
Figure 16. Global Top Neuroendocrine Carcinoma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroendocrine Carcinoma as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Neuroendocrine Carcinoma Revenue in 2019
Figure 18. North America Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Neuroendocrine Carcinoma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Bottom-up and Top-down Approaches for This Report
Figure 26. Data Triangulation
Figure 27. Key Executives Interviewed
神経内分泌がん治療薬の世界市場（～2026年） Market Analysis and Insights: Global Neuroendocrine Carcinoma Drugs Market The global Neuroendocrine Carcinoma Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Neuroendocrine Carcinoma Drugs Scope and Market Size …- 神経内分泌機能検査の世界市場（～2026年） Neuroendocrine function test is a diagnosis process of finding out the neuroendocrine tumor. Based on treatment type, the global neuroendocrine function test market is segmented surgery and medication. As surgery is widely used in the neuroendocrine function test market. Similarly, based on end user…
- 腎細胞がん治療薬の世界市場（～2026年） Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine. RCC is the most common type of kidney cancer in adults, responsible for approximately 90–95% of cases.The drug is …
- 尿路上皮がん診断の世界市場（～2026年） Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. The increasing trends of cigarette smoking is increasing the chances of urothelial carcinoma manifold. Market Analysis and Insights: Global Urot…
- 基底細胞がん（BCC）治療薬の世界市場（～2026年） Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…